Skip to main content

View full-text article in PMC

. 2022 Jun 3;8(8):847–856. doi: 10.1093/ehjcvp/pvac036

Table 2.

Blood chemistry and haematology data. Unless otherwise indicated, n = 5

		Apixaban			Rivaroxaban			Ticagrelor
Parameters	Time (h)	Control	Treatment	P-value	Control	Treatment	P-value	Control	Treatment	P-value
		(Mean ± SD)	(Mean ± SD)		(Mean ± SD)	(Mean ± SD)		(Mean ± SD)	(Mean ± SD)
Blood pH^a	0	7.32 ± 0.02	7.32 ± 0.00	0.92	7.28 ± 0.02	7.29 ± 0.02	0.96	7.36 ± 0.02	7.36 ± 0.02	1.00
	6	7.19 ± 0.00	7.24 ± 0.02	0.07	7.23 ± 0.02	7.25 ± 0.02	0.23	7.27 ± 0.02	7.28 ± 0.04	0.51
Plasma pH^a	0	7.23 ± 0.10	7.21 ± 0.10	0.84	7.20 ± 0.09	7.16 ± 0.1	0.87	7.46 ± 0.07	7.42 ± 0.04	0.31
	6	7.11 ± 0.12	7.20 ± 0.16	0.46	7.08 ± 0.07	7.06 ± 0.1	0.65	7.40 ± 0.11	7.42 ± 0.04	0.72
Total Haemoglobin (g/L)^a	0	90.3 ± 2.0	91.3 ± 2.2	0.87	106.8 ± 0.3	106.8 ± 0.2	1.00	100.0 ± 2.7	96.4 ± 1.6	1.50
	6	84.0 ± 2.2	80.5 ± 2.7	0.65	96.8 ± 0.4	93.6 ± 0.2	0.26	93.4 ± 3.1	89.0 ± 1.6	1.30
Plasma free Haemoglobin	0	0.5 ± 0.7	0.5 ± 0.7	0.77	0.5 ± 0.5	0.5 ± 0.2	0.53	0.4 ± 0.9	0.4 ± 0.4	0.51
(g/L)^a	6	0.4 ± 0.4	0.5 ± 0.7	0.41	0.5 ± 0.5	0.5 ± 0.2	0.25	0.4 ± 0.7	0.3 ± 0.7	0.46
Haematocrit (%)^b	0	31.9 ± 0.0	31.0 ± 0.1	0.72	31.4 ± 3.4	31.4 ± 3.6	0.79	29.4 ± 0.1	29.2 ± 0.0	0.94
	6	30.0 ± 0.0	30.0 ± 0.0	0.85	28.4 ± 2.9	27.6 ± 3.8	0.30	27.4 ± 0.1	26.2 ± 0.0	0.63
Platelets (K/μL)^b	0	341 ± 14.4	328 ± 11.7	0.98	268 ± 7.1	261 ± 9.1	0.86	305 ± 9.9	301 ± 7.1	0.97
	6	269 ± 13.9	183 ± 11.6	0.31	178 ± 14.4	148 ± 12.5	0.56	244 ± 12.7	181 ± 11.3	0.66
White Blood Cells (K/μL)^b	0	6.85 ± 1.5	6.88 ± 1.4	0.99	6.12 ± 0.7	6.06 ± 0.7	0.91	3.95 ± 0.4	3.99 ± 0.5	0.96
	6	5.85 ± 1.4	5.24 ± 1.7	0.73	5.48 ± 0.7	4.90 ± 0.9	0.29	3.69 ± 0.4	3.54 ± 0.4	0.80

^a n = 4 for Apixaban group; ^bn = 2 for Ticagrelor group.